140 related articles for article (PubMed ID: 19688158)
1. Urticaria associated with hyper-IgE in a patient with psoriasis undergoing treatment with efalizumab.
Saraceno R; Scotto G; Chiricozzi A; Chimenti S
Acta Derm Venereol; 2009; 89(4):412-3. PubMed ID: 19688158
[No Abstract] [Full Text] [Related]
2. British Association of Dermatologists guidelines for use of biological interventions in psoriasis 2005.
Smith CH; Anstey AV; Barker JN; Burden AD; Chalmers RJ; Chandler D; Finlay AY; Griffiths CE; Jackson K; McHugh NJ; McKenna KE; Reynolds NJ; Ormerod AD;
Br J Dermatol; 2005 Sep; 153(3):486-97. PubMed ID: 16120132
[No Abstract] [Full Text] [Related]
3. Efficacy of efalizumab in psoriasis patients previously treated with tumour necrosis factor blockers.
Costanzo A; Talamonti M; Botti E; Spallone G; Papoutsaki M; Chimenti S
Dermatology; 2009; 219(1):48-53. PubMed ID: 19372639
[TBL] [Abstract][Full Text] [Related]
4. Etanercept and efalizumab treatment for high-need psoriasis. Effects and side effects in a prospective cohort study in outpatient clinical practice.
Berends MA; Driessen RJ; Langewouters AM; Boezeman JB; Van De Kerkhof PC; De Jong EM
J Dermatolog Treat; 2007; 18(2):76-83. PubMed ID: 17520463
[TBL] [Abstract][Full Text] [Related]
5. Biologic therapy for psoriasis: an update on the tumor necrosis factor inhibitors infliximab, etanercept, and adalimumab, and the T-cell-targeted therapies efalizumab and alefacept.
Weinberg JM; Bottino CJ; Lindholm J; Buchholz R
J Drugs Dermatol; 2005; 4(5):544-55. PubMed ID: 16167412
[TBL] [Abstract][Full Text] [Related]
6. Sustained efficacy and safety of adalimumab in psoriasis treatment: a retrospective study of 49 patients with and without a history of TNF-alpha antagonist treatment.
Van L; Modi SV; Yang DJ; Hsu S
Arch Dermatol; 2008 Jun; 144(6):804-6. PubMed ID: 18559778
[No Abstract] [Full Text] [Related]
7. Recommendations for incorporating biologicals into management of moderate to severe plaque psoriasis: individualized patient approaches.
Langley RG; Ho V; Lynde C; Papp KA; Poulin Y; Shear N; Toole J; Zip C
J Cutan Med Surg; 2006; 9 Suppl 1():18-25. PubMed ID: 16633860
[TBL] [Abstract][Full Text] [Related]
8. A case of tuberculosis in a patient on Efalizumab and Etanercept for treatment of refractory palmopustular psoriasis and psoriatic arthritis.
Kitamura G; Mehr N; Anderson N; Sirichotiratana M
Dermatol Online J; 2009 Feb; 15(2):11. PubMed ID: 19336028
[TBL] [Abstract][Full Text] [Related]
9. Cytomegalovirus complicating biological immunosuppressive therapy in two patients with psoriasis receiving treatment with etanercept or efalizumab.
Petersen B; Lorentzen H
Acta Derm Venereol; 2008; 88(5):523-4. PubMed ID: 18779901
[No Abstract] [Full Text] [Related]
10. Experience with biologics for psoriasis in daily practice: rotational therapy is required.
Saccomani C; Penz S; Guerre-Schmidt R; Pelletier F; Puzenat E; Riou-Gotta MO; Humbert P; Aubin F
J Dermatolog Treat; 2011 Jun; 22(3):151-2. PubMed ID: 20524880
[No Abstract] [Full Text] [Related]
11. An overview of the pharmacokinetics and pharmacodynamics of efalizumab: a monoclonal antibody approved for use in psoriasis.
Joshi A; Bauer R; Kuebler P; White M; Leddy C; Compton P; Garovoy M; Kwon P; Walicke P; Dedrick R
J Clin Pharmacol; 2006 Jan; 46(1):10-20. PubMed ID: 16397279
[TBL] [Abstract][Full Text] [Related]
12. The efficacy and safety of infliximab in patients with plaque psoriasis who had an inadequate response to etanercept: results of a prospective, multicenter, open-label study.
Gottlieb AB; Kalb RE; Blauvelt A; Heffernan MP; Sofen HL; Ferris LK; Kerdel FA; Calabro S; Wang J; Kerkmann U; Chevrier M
J Am Acad Dermatol; 2012 Oct; 67(4):642-50. PubMed ID: 22153792
[TBL] [Abstract][Full Text] [Related]
13. Association between the type and length of tumor necrosis factor inhibitor therapy and myocardial infarction risk in patients with psoriasis.
Wu JJ; Poon KY; Bebchuk JD
J Drugs Dermatol; 2013 Aug; 12(8):899-903. PubMed ID: 23986163
[TBL] [Abstract][Full Text] [Related]
14. [Biologics in the treatment of psoriasis].
Dissemond J; Grabbe S
MMW Fortschr Med; 2006 Sep; 148(38):42-4. PubMed ID: 17036963
[TBL] [Abstract][Full Text] [Related]
15. Immunologic targets in psoriasis.
Kupper TS
N Engl J Med; 2003 Nov; 349(21):1987-90. PubMed ID: 14627782
[No Abstract] [Full Text] [Related]
16. Efalizumab therapy for psoriasis in patients with inadequate responses to etanercept.
Kramer JM; Turner JE
Am J Clin Dermatol; 2009; 10(2):134-40. PubMed ID: 19222255
[TBL] [Abstract][Full Text] [Related]
17. When there is no single best biological agent: psoriasis and psoriatic arthritis in the same patient responding to two different biological agents.
Adişen E; Karaca F; Gürer MA
Clin Exp Dermatol; 2008 Mar; 33(2):164-6. PubMed ID: 18257837
[TBL] [Abstract][Full Text] [Related]
18. Palmoplantar pustular psoriasis: successful therapy with efalizumab after non-response to infliximab.
Wozel G; Vitez L
Acta Derm Venereol; 2008; 88(2):169-70. PubMed ID: 18311451
[No Abstract] [Full Text] [Related]
19. Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis.
Griffiths CE; Strober BE; van de Kerkhof P; Ho V; Fidelus-Gort R; Yeilding N; Guzzo C; Xia Y; Zhou B; Li S; Dooley LT; Goldstein NH; Menter A;
N Engl J Med; 2010 Jan; 362(2):118-28. PubMed ID: 20071701
[TBL] [Abstract][Full Text] [Related]
20. Eruptive latent metastatic melanomas after initiation of antitumor necrosis factor therapies.
Fulchiero GJ; Salvaggio H; Drabick JJ; Staveley-O'Carroll K; Billingsley EM; Marks JG; Helm KF
J Am Acad Dermatol; 2007 May; 56(5 Suppl):S65-7. PubMed ID: 17434043
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
